<?xml version="1.0"?><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:wgs84_pos="http://www.w3.org/2003/01/geo/wgs84_pos" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdaGr2="http://rdvocab.info/ElementsGr2" xmlns:oai="http://www.openarchives.org/OAI/2.0/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:dcterms="http://purl.org/dc/terms/"><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-MHZDI69C/af77058e-2ed4-498c-b19b-4738a0bb50ad/PDF"><dcterms:extent>324 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-MHZDI69C/b8b4088d-d6ca-4e83-8aca-2cfb7c123493/TEXT"><dcterms:extent>30 KB</dcterms:extent></edm:WebResource><edm:TimeSpan rdf:about="2005-2025"><edm:begin xml:lang="en">2005</edm:begin><edm:end xml:lang="en">2025</edm:end></edm:TimeSpan><edm:ProvidedCHO rdf:about="URN:NBN:SI:doc-MHZDI69C"><dcterms:isPartOf rdf:resource="https://www.dlib.si/details/URN:NBN:SI:spr-8ER5ZBJN" /><dcterms:issued>2016</dcterms:issued><dc:creator>Devjak Novak, Sabina</dc:creator><dc:creator>Košir, Darjan</dc:creator><dc:creator>Vrečer, Franc</dc:creator><dc:format xml:lang="sl">številka:4</dc:format><dc:format xml:lang="sl">letnik:67</dc:format><dc:format xml:lang="sl">str. 273-280</dc:format><dc:identifier>ISSN:0014-8229</dc:identifier><dc:identifier>COBISSID:4101745</dc:identifier><dc:identifier>URN:URN:NBN:SI:doc-MHZDI69C</dc:identifier><dc:language>sl</dc:language><dc:publisher xml:lang="sl">Slovensko farmacevtsko društvo</dc:publisher><dcterms:isPartOf xml:lang="sl">Farmacevtski vestnik</dcterms:isPartOf><dc:subject xml:lang="en">drug</dc:subject><dc:subject xml:lang="sl">farmacevtski pripravki</dc:subject><dc:subject xml:lang="sl">funkcionalnost pomožnih snovi</dc:subject><dc:subject xml:lang="sl">hipromeloza</dc:subject><dc:subject xml:lang="sl">lastnosti pomožnih snovi</dc:subject><dc:subject xml:lang="sl">pomožne snovi</dc:subject><dc:subject xml:lang="sl">zdravila</dc:subject><dc:subject rdf:resource="http://www.wikidata.org/entity/Q12140" /><dcterms:temporal rdf:resource="2005-2025" /><dc:title xml:lang="sl">S funkcionalnostjo povezane lastnosti hipromeloze kot tvorilca hidrofilnih ogrodnih tablet| Functionality-related characteristics of hypromellose used as a matrix forming agent|</dc:title><dc:description xml:lang="sl">Pharmaceutical excipents are essential components of dosage forms. The key physico-chemical properties of functional excipients should be identified, and the influence of their variability on the properties of the final dosage form should be evaluated during the de- velopment phase. The European Pharmacopeia (6.1) has introduced a nonmandatory functionality related characteristics (FRCs) sections in certain excipient monographs. Data obtained from literature and our results prove that FRCs sections are not only addi- tional testing, but they also contribute to the quality of a medicinal product and to the understanding which FRC parameter is critical for the intended use or intended formulation. Correct understanding and evaluation of physico-chemical characteristics of ex- cipients in pre-formulation study are critical for safe, non-toxic and effective medicine product</dc:description><dc:description xml:lang="sl">Pomožne snovi so bistvene sestavine farmacevtskih oblik. Zaradi tega je treba v fazi razvoja vsakega no- vega izdelka natančno proučiti njihove fizikalno-ke- mijske lastnosti in njihov vpliv na kakovost končnega izdelka. S tem namenom so v 6. dopolnilo (6.1) Ev- ropske farmakopeje njeni snovalci vključili novo splo- šno poglavje z naslovom S funkcionalnostjo povezane lastnosti (FRC lastnosti) pomožnih snovi. Predstavljeni literaturni podatki in rezultati lastnega proučevanja s funkcionalnostjo povezanih lastnosti na primeru hi- promeloze dokazujejo, da uvedeni FRC razdelki ne prinašajo zgolj dodatnega testiranja, ampak bistveno pripomorejo k pravilnemu razumevanju, katere FRC lastnosti posamezne pomožne snovi so kritične za nameravano uporabo v formulacijah. Pravilno razu- mevanje in ovrednotenje fizikalno-kemijskih lastnosti pomožnih snovi že v predformulacijskih študijah no- vega izdelka tako bistveno pripomorejo h kakovosti, varnosti in učinkovitosti zdravila</dc:description><edm:type>TEXT</edm:type><dc:type xml:lang="sl">znanstveno časopisje</dc:type><dc:type xml:lang="en">journals</dc:type><dc:type rdf:resource="http://www.wikidata.org/entity/Q361785" /></edm:ProvidedCHO><ore:Aggregation rdf:about="http://www.dlib.si/?URN=URN:NBN:SI:doc-MHZDI69C"><edm:aggregatedCHO rdf:resource="URN:NBN:SI:doc-MHZDI69C" /><edm:isShownBy rdf:resource="http://www.dlib.si/stream/URN:NBN:SI:doc-MHZDI69C/af77058e-2ed4-498c-b19b-4738a0bb50ad/PDF" /><edm:rights rdf:resource="http://rightsstatements.org/vocab/InC/1.0/" /><edm:provider>Slovenian National E-content Aggregator</edm:provider><edm:intermediateProvider xml:lang="en">National and University Library of Slovenia</edm:intermediateProvider><edm:dataProvider xml:lang="sl">Slovensko farmacevtsko društvo</edm:dataProvider><edm:object rdf:resource="http://www.dlib.si/streamdb/URN:NBN:SI:doc-MHZDI69C/maxi/edm" /><edm:isShownAt rdf:resource="http://www.dlib.si/details/URN:NBN:SI:doc-MHZDI69C" /></ore:Aggregation></rdf:RDF>